Cargando…

Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation

OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence v...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestre, Ramona A., Almería Lafuente, Alejandro, Jiménez-Mendiguchía, Lucía, García-Cano, Ana, Romero López, Rubén, García-Izquierdo, Belén, Pardo de Santayana, Cristina, Iglesias, Pedro, Diez, Juan J., Arribas Gómez, Ignacio, Bernabeu-Andreu, Francisco A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197409/
https://www.ncbi.nlm.nih.gov/pubmed/37363331
http://dx.doi.org/10.1515/almed-2021-0015
_version_ 1785044545989246976
author Silvestre, Ramona A.
Almería Lafuente, Alejandro
Jiménez-Mendiguchía, Lucía
García-Cano, Ana
Romero López, Rubén
García-Izquierdo, Belén
Pardo de Santayana, Cristina
Iglesias, Pedro
Diez, Juan J.
Arribas Gómez, Ignacio
Bernabeu-Andreu, Francisco A.
author_facet Silvestre, Ramona A.
Almería Lafuente, Alejandro
Jiménez-Mendiguchía, Lucía
García-Cano, Ana
Romero López, Rubén
García-Izquierdo, Belén
Pardo de Santayana, Cristina
Iglesias, Pedro
Diez, Juan J.
Arribas Gómez, Ignacio
Bernabeu-Andreu, Francisco A.
author_sort Silvestre, Ramona A.
collection PubMed
description OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence vs. standard TRACE-immunofluorescence; (ii) to determine the diagnostic validity of the three methods. METHODS: A retrospective study in 194 patients with a TRAb determination request. TRAb were determined by immunofluorescence (Kryptor, ThermoFisher) and chemiluminescence (Immulite, Siemens and Maglumi, Snibe). Clinical validation: medical records were reviewed and categorized according to thyroid function. Statistical analysis: Differences in quantitative variables were assessed by intraclass correlation coefficient, Bland–Altman plot, and mean differences (mD). Qualitative variables were dichotomized by cut-off points; Kappa coefficient was calculated. Correlations were evaluated by Pearson’s coefficient and Passing-Bablok regression analysis. The diagnostic validity of the three methods was investigated. RESULTS: Kryptor-Immulite: mD: 1.2 (95%CI: −16 to >18). Passing-Bablok: Constant error (95%CI: −0.8349 to −0.5987). Proportional error (95%CI: 0.7862–1.0387). ICC: 0.86 (95%CI: 0.82–0.89). Kappa coefficient: 0.68 (95%CI 0.59–0.78). Kryptor-Maglumi: mD: −0.3 (95%CI: −12 to >12). Passing-Bablok: Constant error (95%CI: −0.7701 to >0.1621. Proportional error (95%CI: 0.8571 to 1.3179. ICC: 0.93 (95%CI: 0.89–0.97). Kappa coefficient: 0.53 (95%CI: 0.32–0.74). Diagnosis of Graves’ disease was confirmed in 113 patients (Kryptorf showed better specificity and positive predictive value, whereas Immulite demonstrated better sensitivity and negative predictive value). CONCLUSIONS: The three methods have a good diagnostic performance for Graves’ disease, with superimposable results on Bland–Altman plot. Interchangeability was not confirmed on the regression and agreement analysis, with the presence of biases.
format Online
Article
Text
id pubmed-10197409
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-101974092023-06-23 Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation Silvestre, Ramona A. Almería Lafuente, Alejandro Jiménez-Mendiguchía, Lucía García-Cano, Ana Romero López, Rubén García-Izquierdo, Belén Pardo de Santayana, Cristina Iglesias, Pedro Diez, Juan J. Arribas Gómez, Ignacio Bernabeu-Andreu, Francisco A. Adv Lab Med Article OBJECTIVES: Graves’ disease is secondary to the presence of anti-thyrotropin receptor antibodies (TRAb), which stimulate thyroid hormones. TRab determination is crucial for etiological diagnosis. The objectives of this study were (i) to compare two methods for determining TRab by chemoluminiscence vs. standard TRACE-immunofluorescence; (ii) to determine the diagnostic validity of the three methods. METHODS: A retrospective study in 194 patients with a TRAb determination request. TRAb were determined by immunofluorescence (Kryptor, ThermoFisher) and chemiluminescence (Immulite, Siemens and Maglumi, Snibe). Clinical validation: medical records were reviewed and categorized according to thyroid function. Statistical analysis: Differences in quantitative variables were assessed by intraclass correlation coefficient, Bland–Altman plot, and mean differences (mD). Qualitative variables were dichotomized by cut-off points; Kappa coefficient was calculated. Correlations were evaluated by Pearson’s coefficient and Passing-Bablok regression analysis. The diagnostic validity of the three methods was investigated. RESULTS: Kryptor-Immulite: mD: 1.2 (95%CI: −16 to >18). Passing-Bablok: Constant error (95%CI: −0.8349 to −0.5987). Proportional error (95%CI: 0.7862–1.0387). ICC: 0.86 (95%CI: 0.82–0.89). Kappa coefficient: 0.68 (95%CI 0.59–0.78). Kryptor-Maglumi: mD: −0.3 (95%CI: −12 to >12). Passing-Bablok: Constant error (95%CI: −0.7701 to >0.1621. Proportional error (95%CI: 0.8571 to 1.3179. ICC: 0.93 (95%CI: 0.89–0.97). Kappa coefficient: 0.53 (95%CI: 0.32–0.74). Diagnosis of Graves’ disease was confirmed in 113 patients (Kryptorf showed better specificity and positive predictive value, whereas Immulite demonstrated better sensitivity and negative predictive value). CONCLUSIONS: The three methods have a good diagnostic performance for Graves’ disease, with superimposable results on Bland–Altman plot. Interchangeability was not confirmed on the regression and agreement analysis, with the presence of biases. De Gruyter 2021-03-02 /pmc/articles/PMC10197409/ /pubmed/37363331 http://dx.doi.org/10.1515/almed-2021-0015 Text en © 2021 Ramona A. Silvestre et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Article
Silvestre, Ramona A.
Almería Lafuente, Alejandro
Jiménez-Mendiguchía, Lucía
García-Cano, Ana
Romero López, Rubén
García-Izquierdo, Belén
Pardo de Santayana, Cristina
Iglesias, Pedro
Diez, Juan J.
Arribas Gómez, Ignacio
Bernabeu-Andreu, Francisco A.
Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title_full Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title_fullStr Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title_full_unstemmed Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title_short Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation
title_sort comparison of three methods for determining anti-thyrotropin receptor antibodies (trab) for diagnosis of graves’ disease: a clinical validation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197409/
https://www.ncbi.nlm.nih.gov/pubmed/37363331
http://dx.doi.org/10.1515/almed-2021-0015
work_keys_str_mv AT silvestreramonaa comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT almerialafuentealejandro comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT jimenezmendiguchialucia comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT garciacanoana comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT romerolopezruben comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT garciaizquierdobelen comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT pardodesantayanacristina comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT iglesiaspedro comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT diezjuanj comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT arribasgomezignacio comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation
AT bernabeuandreufranciscoa comparisonofthreemethodsfordeterminingantithyrotropinreceptorantibodiestrabfordiagnosisofgravesdiseaseaclinicalvalidation